Literature DB >> 3847289

Effect of a thymic factor, thymostimulin, on growth and pulmonary metastases of Lewis lung carcinoma.

M Yagi, T Yamashita, E Tsubura.   

Abstract

The antitumor and antimetastatic activities of a thymic factor, thymostimulin (TP-1), with or without cyclophosphamide (CPA) were examined in C57BL/6 mice inoculated with Lewis lung carcinoma (3LL). Tumor growth was followed by determining the tumor diameter after tumor implantation. TP-1 given to mice every 2 days after tumor implantation significantly inhibited tumor growth without affecting the survival rate. For induction of spontaneous pulmonary metastases, 3LL cells were implanted into the footpads of mice, and the implanted tumor was removed on day 9. The antimetastatic effect of TP-1 on pulmonary metastases after removal of the primary tumor was evaluated by counting the number of pulmonary surface nodules. TP-1 showed antimetastatic activity depending on its time of administration and dose. Combined therapy with TP-1 plus CPA significantly prolonged the survival of mice with pulmonary metastases. The cytolytic activities of spleen cells on 3LL cells were enhanced in mice treated with TP-1 and/or CPA and the cytolytic activity of nonadherent spleen cells, the T-cell population, was enhanced. The role of cytolytic spleen cells in inhibiting and preventing metastases was discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3847289     DOI: 10.1007/bf00199226

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course.

Authors:  S D Lipson; P B Chretien; R Makuch; D E Kenady; M H Cohen
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

2.  Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.

Authors:  M H Cohen; P B Chretien; D C Ihde; B E Fossieck; R Makuch; P A Bunn; A V Johnston; S E Shackney; M J Matthews; S D Lipson; D E Kenady; J D Minna
Journal:  JAMA       Date:  1979-04-27       Impact factor: 56.272

3.  Observations on thymectomy and carcinogenesis.

Authors:  A C Allison; R B Taylor
Journal:  Cancer Res       Date:  1967-04       Impact factor: 12.701

4.  Immunologic responsiveness and the induction of experimental neoplasms.

Authors:  L W Law
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

5.  Influence of immunologic competence of the host on metastases induced by the 3LL Lewis tumor in mice.

Authors:  C Carnaud; B Hoch; N Trainin
Journal:  J Natl Cancer Inst       Date:  1974-02       Impact factor: 13.506

6.  The in vivo effect of a thymic factor (thymostimulin) on immunologic parameters of patients with untreated Hodgkin's disease.

Authors:  M F Martelli; A Velardi; P Rambotti; C Cernetti; A Bertotto; F Spinozzi; A M Bracaglia; B Falini; S Davis
Journal:  Cancer       Date:  1982-08-01       Impact factor: 6.860

7.  Effect of cyclophosphamide on the immune response of BALB/c mice bearing an immunoglobulin M plasmacytoma (TEPC-183).

Authors:  H F Havas; G Schiffman
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

8.  Inhibition of pulmonary metastasis of Lewis lung carcinoma by a glucan, Schizophyllan.

Authors:  T Yamamoto; T Yamashita; E Tsubura
Journal:  Invasion Metastasis       Date:  1981

9.  Ability of lymphocytes treated with thymic factor to decrease lung metastasis in tumor-bearing mice.

Authors:  D Cupissol; J L Touraine; B Serrou
Journal:  Thymus       Date:  1981-06

10.  Inhibition of pulmonary metastasis by Nocardia rubra cell wall skeleton, with special reference to macrophage activation.

Authors:  K Kagawa; T Yamashita; E Tsubura; Y Yamamura
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

View more
  3 in total

1.  Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases.

Authors:  K Yamasaki; S Sone; T Yamashita; T Ogura
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Thymic factor-induced reduction of pulmonary metastases in mice with FSA-1 fibrosarcoma.

Authors:  V J Tomazic; C R Sacasa; A Loftus; C S Suter; G E Elias
Journal:  Clin Exp Metastasis       Date:  1988 Jan-Feb       Impact factor: 5.150

3.  Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.

Authors:  K Fukuta; S Sone; M Kitahara; M Okada; T Ogura
Journal:  Jpn J Cancer Res       Date:  1989-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.